Abstract
FDA approval of the first device to use novel biomarkers of kidney damage to assess risk of acute kidney injury (AKI) potentially brings forward diagnosis of moderate-to-severe AKI to a time frame that could enable early intervention. Although the device awaits greater scrutiny, its approval marks the beginning of a new era.
MeSH terms
-
Acute Kidney Injury / diagnosis*
-
Acute Kidney Injury / pathology
-
Acute Kidney Injury / prevention & control
-
Acute Kidney Injury / urine*
-
Biomarkers / urine
-
Cell Cycle Checkpoints*
-
Early Diagnosis*
-
Female
-
Fluoroimmunoassay / methods
-
Humans
-
Insulin-Like Growth Factor Binding Proteins / urine*
-
Male
-
Matrix Metalloproteinase 2 / urine*
-
Point-of-Care Systems
-
Sensitivity and Specificity
-
United States
-
United States Food and Drug Administration
Substances
-
Biomarkers
-
Insulin-Like Growth Factor Binding Proteins
-
Matrix Metalloproteinase 2